Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiangnan Qiang
Observed name:
xiangnan qiang
Institution:
WuXi AppTec (China)
Observed institutions:
WuXi AppTec (China),
WuXi AppTec (United States)
OpenAlex ID:
A5057507617
1162 Upregulation of metabolism enzymes mediatesADC resistance in a HER2-positive cancer cell line
2023
·
Dong Wang
, Xiangnan Qiang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)
2023
·
Xiangnan Qiang
, Ronghua Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models
2023
·
Ting Ni
, Tongxin Huo
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 4673: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
2023
·
Hui Qi
, Fuyang Wang
, et al.
·
Cancer Research
·
1
Abstract 260: EpCAM-CD3 bispecific antibody-encoding mRNA delivered by lung targeted lipid nanoparticles suppresses orthotopic lung tumor growth.
2026
·
Dong Wang
, Gang Liu
, et al.
·
Cancer Research
Abstract 1863: Development and characterization of the venetoclax-resistant AML model to enable preclinical drug discovery.
2026
·
Jifan Yuan
, Miaomiao Yu
, et al.
·
Cancer Research
Abstract 5828: Development of NK humanized mice models for the in vivo evaluation of NK cell-based therapeutics
2025
·
Dong Wang
, zhixiang zhang
, et al.
·
Cancer Research
Development, Characterization, and Therapeutic Utility of Paclitaxel‐Resistant Breast and Gastric Cancer In Vitro and In Vivo Models
2025
·
Feng Tang
, Hong Xu
, et al.
·
Current Protocols
478 NLRP3 inhibitor treatment reverses melanoma-induced vitiligo in mice
2024
·
Yaxin Cai
, Limei Zhao
, et al.
·
Journal for ImmunoTherapy of Cancer
Abstract 3257: Unleashing immune power: How mRNA-encoded modulators suppress tumor growth
2024
·
Dong Wang
, zhixiang zhang
, et al.
·
Cancer Research
Abstract 542: Development of novel syngeneic tumor models with intrinsic or extrinsic resistance mechanisms to PD-1 blockade
2024
·
Xiaomin Wang
, Ziwei Zhang
, et al.
·
Cancer Research
446 The administration of JAK and TYK2 inhibitor successfully ameliorated the severity of T cell transfer-induced colitis in mice
2023
·
Chunhui He
, Yanping Yuan
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
452 Braicitinib treatment reduced the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata
2023
·
Hao Yi
, Xiao Jian
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
59 Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics
2023
·
Dong Wang
, Xiangnan Qiang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 4988: A tailored platform enables BRAF-targeted drug discovery and precision medicine
2023
·
Hui Qi
, Fuyang Wang
, et al.
·
Cancer Research
Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery
2023
·
Nengwei Xu
, Reifeng Wang
, et al.
·
Cancer Research
Abstract 1055: Evaluation of immune checkpoint inhibitor efficacy in EGFR mutant tumors
2019
·
Xuzhen Tang
, Li Yang
, et al.
·
Cancer Research
Abstract 1055: Evaluation of immune checkpoint inhibitor efficacy in EGFR mutant tumors
2019
·
Xuzhen Tang
, Li Yang
, et al.
·
Tumor Biology
Abstract 4759: Identification of ALK, ROS1, FGFR2 and NRG1 fusions and validation with targeted inhibitors in lung and ovarian PDX models
2016
·
Xuzhen Tang
, Hua Dong
, et al.
·
Cancer Research
Abstract 82: Genomic profiling of PDX models across 14 tumor types reveals novel targeted therapeutic opportunities
2016
·
Hua Dong
, Zhixiang Zhang
, et al.
·
Cancer Research
Show more works
View as search
Works count:
20
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type